

ESTRO 36, 5-9 MAY 2017, VIENNA, AUSTRIA

Legend:

	Interdisciplinary session
	Radiobiology session
	Young scientists' session
	Clinical session
	Physics session
	Brachytherapy session
	RTT session

SATURDAY, 6 MAY 2017

08:00-08:40	<p>Teaching Lecture</p> <p>The role of radiotherapy in small cell lung cancer-current status and future developments</p> <p>Chair: U. Nestle (DE)</p> <p>Speaker: R. Dziadziuszko (PL)</p>	<p>Teaching Lecture</p> <p>Immunotherapy</p> <p>Chair: J. Bussink (NL)</p> <p>Speaker: G. Coukos (CH)</p>	<p>Teaching Lecture</p> <p>MRI for RO physicists: what is what? QA geometrical distortions</p> <p>Chair: M. Philippens (NL)</p> <p>Speaker: E. Paulson (US)</p>	<p>Teaching Lecture</p> <p>Cavity Theory: How can we separate the facts from the myths?</p> <p>Chair: N. Jornet (ES)</p> <p>Speaker: A. Nahum (SE)</p>	<p>Teaching Lecture</p> <p>High tech or low tech for metastatic disease, how does one decide and what is the cost-benefit?</p> <p>Chair: C. Dickie (CA)</p> <p>Speaker: Y. van der Linden (NL)</p>	<p>Teaching Lecture</p> <p>Gene editing: How this technique can be used to study radiation responses?</p> <p>Chair: R. Bristow (CA)</p> <p>Speaker TBC</p>	<p>Teaching lecture</p> <p>Target delineation and target definition for PBI</p> <p>Chair: E. Van Limbergen (BE)</p> <p>Target delineation and target definition for PBI after closed cavity surgery and oncoplastic surgery</p> <p>Speaker: V. Strnad (DE)</p> <p>Target delineation and target definition for PBI after open cavity surgery</p> <p>Speaker: T. Major (HU)</p>		
08:45-10:00	<p>Joint Symposium ESTRO-ASTRO</p> <p>Cutting edge combined</p>	<p>Symposium with proffered papers</p> <p>Radiotherapy plus immunotherapy</p>	<p>Symposium</p> <p>New technological and computational developments</p>	<p>Symposium</p> <p>CT imaging, new developments</p> <p>Chair: T. Nyholm</p>	<p>Symposium</p> <p>High tech or low tech for metastatic disease, how does one</p>	<p>Symposium with proffered papers</p> <p>Novel approaches in heart matters</p>	<p>Symposium</p> <p>Expanding brachytherapy indications</p> <p>Chair: C.</p>		Poster Viewing 1

	<p>modality therapies</p> <p>The gains to be made by combined modality treatment in NSCLC: setting the scene of new possibilities <i>Speaker TBC</i></p> <p>The use of biomarkers for individualised treatment in NSCLC <i>Speaker TBC</i></p> <p>Radiotherapy and immunotherapy in NSCLC: results to date, questions to consider <i>Speaker TBC</i></p> <p>The use of novel technologies (e.g. protons) in NSCLC <i>Speaker TBC</i></p>	<p>combination: rationale and results so far</p> <p>Chair: R. Nout (NL)</p> <p>The immune-modulatory effect of radiotherapy on the tumour micro-environment: friend or foe? <i>GJ Adema (NL)</i></p> <p>The impact of tumour infiltrating lymphocytes on clinical outcome after (chemo)radiotherapy <i>J. Galon (FR)</i></p> <p>Radiotherapy and immunotherapy combination: paradigm changing or just hype? <i>S. Dovedi (UK)</i></p> <p>+ 1-2 proffered papers</p>	<p>in particle therapy</p> <p>Chair: M. Schwarz (IT)</p> <p>Scaling down proton therapy facilities to fit into photon vaults <i>T. Bortfeld (US)</i></p> <p>Integrating CBCT in ion beam therapy: challenges and opportunities beyond anatomical guidance <i>K. Teo (US)</i></p> <p>New horizons in probabilistic and robust treatment planning in particle therapy <i>M. Alber (DK)</i></p>	<p>(SE)</p> <p>Current status and potential of dual energy and spectral CT <i>J. Andersson (SE)</i></p> <p>CT image quality: using a model observer for clinically relevant optimisation <i>N. Ryckx (CH)</i></p> <p>The potential of new CT technologies for radiotherapy with photons and protons <i>W. van Elmpt (NL)</i></p>	<p>decide and what is the cost-benefit?</p> <p>Chair: M. Coffey (IE)</p> <p>High tech approaches for curative treatment, when is enough enough? <i>J. Kazmierska (PL)</i></p> <p>Palliative workflow <i>M. Kamphuis (NL)</i></p> <p>Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy / radiosurgery: QUIRO-DEGRO trial <i>A. Zabel-du Bois (DE)</i></p>	<p>Chair: P. van Luijk (NL)</p> <p>State of the art in heart effects <i>MC Vozenin (CH)</i></p> <p>Pharmacological modulation of cardiac radiation injury <i>M. Boerma (US)</i></p> <p>+ 3 proffered papers</p>	<p>Chargari (FR)</p> <p>The technique for CT/MR guided hepatic implantations <i>N. Tselis (DE)</i></p> <p>Optical and tracking technologies for navigation in brachytherapy <i>R. Weersink (CA)</i></p> <p>Using multiparametric US to redefine target volumes in brachytherapy <i>H. Wijkstra (NL)</i></p>		
10:00-10:30	Coffee Break								
10:30-11:30	<p>Multi-disciplinary Tumour Board</p> <p>HNSCC</p>	<p>Symposium with proffered papers</p> <p>Response adapted treatment</p> <p>Chair: JJ Sonke (NL)</p> <p>Mechanisms and biomarkers of tumour response heterogeneity <i>S. Chopra (IN)</i></p>	Proffered Papers	Proffered Papers	Proffered Papers	<p>Symposium with proffered papers</p> <p>Novel approaches in gut matters</p> <p>Chair: A. Kiltie (UK)</p> <p>State of the art in gut effects <i>TBC</i></p> <p>Bowel radiation injury:</p>	Proffered Papers	Proffered Papers	Poster Viewing 2

		Response optimised treatment planning and guidance <i>B. Vanderstraeten (BE)</i> Current status and future perspective of response adaptation <i>D. Zips (DE)</i> + 1-2 proffered papers				Complexity of the pathophysiology and promises of cell and tissue engineering <i>L. Moussa (FR)</i> + 1 proffered paper			
11:40-12:10	Van der Schueren Award Lecture <i>B. Heijmen (NL)</i>								
12:10-12:40	Iridium Award Lecture <i>J. Venselaar (NL)</i>								
12:40-13:00	Honorary Physicist Award Lecture <i>V. Valentini (IT)</i>								
13:00-14:45	13:30-14:30 Physics Members Assembly Lunch, Satellite Symposium, Poster Viewing								
14:45-16:00	Symposium The optimal approach to treat oligometastatic disease: different ways to handle an indication quickly gaining acceptance Chair: M. Guckenberger (CH) Clinical approach to abscopal effects <i>P. Lara (ES)</i> What is the	Symposium with proffered papers Targeting tumour heterogeneity Chair: B. Pieters (NL) Using heterogeneous brachytherapy dose distribution to target tumour cell heterogeneity <i>R. Alonzi (UK)</i> The challenges of targeting tumour heterogeneity in the field of radiation oncology <i>P. Lambin (NL)</i> The impact of	Symposium Innovations in ion beam therapy Chair: L. Muren (DK) Reducing range uncertainties: new approaches for stopping power determination and in-vivo range verification <i>K. Parodi (DE)</i> Mechanisms and Models of Particle Relative Biological Effectiveness (RBE) <i>D. Carlson (US)</i>	Symposium Imaging for therapeutic response / toxicity evaluation Chair: U. van der Heide (NL) Functional imaging as biomarker for toxicity response <i>Y. Cao (US)</i> Imaging tumour response to neoadjuvant treatment in GI tumours <i>G. Meijer (NL)</i> Imaging biomarkers to predict and early	Symposium Comprehensive motion management and immobilisation solutions in radiation therapy Chair: B. Bak (PL) Immobilising the patient to be as comfortable as possible. A general overview <i>A. Osztavics (AT)</i> Motion control of the patient, using the exactrac system <i>K. Szczesna (PL)</i>	Symposium with proffered papers Novel approaches in brain matters Chair: R. Coppes (NL) Effect of radiation on CNS stem cells <i>L. Barazzuol (UK)</i> The cognitive defects of neonatally irradiated mice are accompanied by changes in adult neurogenesis <i>S. Tapio (DE)</i> + 3 proffered	Symposium Brachytherapy pays Chair: LT Tan (UK) Introducing the GEC-HERO initiative <i>LT Tan (UK)</i> Review of health related quality of life measures with brachytherapy and application to QALY for economic evaluation <i>H. Kim (US)</i> Optimal utilisation of brachytherapy in		Poster Viewing 3

	<p>purpose of surgical metastasectomy and do we achieve it? <i>T. Treasure (UK)</i></p> <p>What is the indication and what is the aim of clinical treatment: radiotherapy <i>E. Lartigau (FR)</i></p> <p>Oligometastatic cancer: a therapeutic challenge <i>K. van der Hoeven (NL)</i></p>	<p>tumour heterogeneity on radiation therapy outcomes <i>M. Gerlinger (UK)</i></p> <p>+ 1-2 proffered papers</p>	<p>New horizons in radiobiology: from RBE to “new biology” <i>M. Durante (IT)</i></p>	<p>assess the response to radiation therapy. Potential impact of studies in small animals <i>B. Gallez (BE)</i></p>	<p>Motion of liver tumours using Active Breathing Control: Keeping the margins small and the patient comfortable <i>M. Mast (NL)</i></p>	<p>papers</p>	<p>Europe - can it be measured? <i>J. Borras (ES)</i></p> <p>Economic evaluation of radiotherapy including brachytherapy for cancer – pitfalls <i>Speaker TBC</i></p>		
16:00-16:30	Coffee Break								
16:30-17:30	<p>Proffered Papers</p>	<p>Joint Symposium ESTRO-JASTRO</p> <p>Oligometastatic disease</p> <p>Chair: Y. Lievens (BE) Chair: Y. Nishimura (JP)</p> <p>Biological rationale and clinical evidence <i>P. Ost (BE)</i></p> <p>Radiophysics implementation: pitfalls and tricks <i>D. Verellen (BE)</i></p> <p>Interpretation and management of oligometastases <i>H. Onishi (JP)</i></p> <p>SBRT for oligometastases <i>T. Kimura (JP)</i></p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Symposium</p> <p>Novel approaches in particle biology</p> <p>Chair: M. Pruschy (CH)</p> <p>The ESTRO initiative on biological effects of particle therapy <i>B. Singers Sorensen (DK)</i></p> <p>RBE of protons <i>B. Jones (UK)</i></p> <p>A small animal tumour model for low-energy laser-accelerated particles <i>J. Pawelke (DE)</i></p> <p>Novel models in particle biology research</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Poster Viewing 4</p>

						<i>P. van Luijk (NL)</i>			
17:40-18:25	Honorary Members' Award Lectures Optimising the treatment of oropharyngeal cancer: the difficult journey back <i>B. O'Sullivan (CA)</i> Potential of radiation therapy to convert the tumor into an <i>in situ</i> vaccine <i>S. Formenti (US)</i> Title TBC <i>J. Izewska (AT)</i>								
18:30-19:30	Poster Awards Ceremony								

SUNDAY, 7 MAY 2017

08:00 - 08:40	<p>Teaching Lecture</p> <p>Role of radiotherapy in extranodal lymphomas</p> <p>Chair: J. Kazmierska (PL)</p> <p>Speaker: L. Specht (DK)</p>	<p>Teaching Lecture</p> <p>Strategies to increase safety in radiation oncology: how to make accidents less likely to occur</p> <p>Chair: L. Fog (DK)</p> <p>Speaker: P. Scalliet (BE)</p>	<p>Teaching Lecture</p> <p>Automated planning, knowledge-based planning and other novel developments in treatment planning - how do they work and perform?</p> <p>Chair: B. Vanderstraeten (BE)</p> <p>Speaker: B. Heijmen (NL)</p>	<p>Teaching Lecture</p> <p>Building of NTCP models that contain non-dosimetric parameters</p> <p>Chair: TBC</p> <p>Speaker: T. Rancati (IT)</p>	<p>Teaching Lecture</p> <p>Particle therapy: how to start up and carry out daily clinical practice</p> <p>Chair: A. Boejen (DK)</p> <p>Speaker: W. Enghardt (DE)</p>	<p>Teaching Lecture</p> <p>Three-dimensional organoid culture system</p> <p>Chair: M. Boerma (US)</p> <p>Speaker: N. Cordes (DE)</p>	<p>Teaching lecture</p> <p>Commissioning of dose calculations in brachytherapy TPS</p> <p>Chair: AC Tedgren (SE)</p> <p>Speaker: J. Steenhuijsen (NL)</p>		
08:45-10:00	<p>Symposium</p> <p>New developments in Personalised Radiation Oncology (PRO)</p> <p>Chair: D. Zips (DE)</p> <p>E-health and Personalised Radiation Oncology: Mobile technology and wearable sensors TBC</p> <p>Integration and analysis of complex data for Personalised Radiation Oncology A. Dekker (NL)</p> <p>Innovative clinical trial designs for</p>	<p>Symposium with proffered papers</p> <p>Safety and clinical and cost effectiveness of multi-modality IGRT and ART</p> <p>Chair: X. Geets (BE)</p> <p>What evidence is needed to assess cost-effectiveness of new technology and how can we get it (easily)? M. Pijls-Johannesma (NL)</p> <p>Tips and tricks for safe and effective routine clinical application F. Duprez (BE)</p>	<p>Symposium</p> <p>Robust optimisation in protons and photons</p> <p>Chair: B. Heijmen (NL)</p> <p>What is the actual robustness of plans we deliver in clinical particle therapy practice and what measures do we take to obtain it S. Molinelli (IT)</p> <p>Minimax robust optimisation applied to IMPT for oropharyngeal tumours S. van de Water (NL)</p> <p>Clinical implementation of coverage</p>	<p>Symposium</p> <p>Ultra fast online therapy adaptation (replanning, dose accumulation QA)</p> <p>Chair: U. Oelfke (UK)</p> <p>Automatic image segmentation for on-line adaptive RT S. Mutic (US)</p> <p>Ultrafast treatment planning and dose reconstruction P. Ziegenhein (UK)</p> <p>Online tumour tracking – technology and quality assurance TBC</p>	<p>Symposium</p> <p>Particle therapy: how to start up and carry out daily clinical practice</p> <p>Chair: A. Vaandering (BE)</p> <p>RTTs skills for proton therapy – how and what to include in a learning programme A. Boejen (DK)</p> <p>How to start up a proton therapy department – the point of view of a RTT M. Furberg (SE)</p> <p>Workflow in a proton therapy department – real difference from photon</p>	<p>Symposium with proffered papers</p> <p>Combining tumour and normal tissue models</p> <p>Chair: MC Vozenin (CH)</p> <p>Novel approaches in the study of bladder cancer A. Kiltie (UK)</p> <p>Combining tumour and lung tissue radiation E. Deutsch (FR)</p> <p>+ 3 proffered papers</p>	<p>Symposium</p> <p>Paediatric brachytherapy</p> <p>Chair: V. Strnad (DE)</p> <p>The AMORE concept and late effects outcome for pediatric head and neck brachytherapy B. Pieters (NL)</p> <p>Brachytherapy for bladder/prostate rhabdomyosarcoma: clinical outcome and functional results C. Chargari (FR)</p> <p>Intraoperative HDR brachytherapy for pediatric cancers S. Wolden (US)</p>		Poster Viewing 5

	<p>Personalised Radiation Oncology <i>S. Brown (UK)</i></p> <p>Decision support systems and shared decision making <i>A. Gambacorta (IT)</i></p>	<p>Do we have the (software) tools for safe application? <i>N. Jornet (ES)</i></p> <p>Development of procedures for safe clinical application of plan-of-the-day adaptive radiotherapy <i>S. Quint (NL)</i></p> <p>+ 1-2 proffered papers</p>	<p>probability planning in cervix cancer <i>J. Lindegaard (DK)</i></p>		<p>therapy? <i>F. Fellin (IT)</i></p>				
10:00-10:30	Coffee Break								
10:30-11:30	<p>Multidisciplinary Tumour Board</p> <p>Lymphoma</p>	<p>Joint Symposium ESTRO-CARO</p> <p>Waiting times and QA</p> <p>Driving Radiotherapy Quality Improvement: The Canadian experience <i>Speaker TBC</i></p> <p>Radiotherapy Quality Improvement across Europe: variable approaches, united view <i>Speaker TBC</i></p> <p>Waiting time in radiotherapy: surrogate of access and outcome indicator <i>Speaker TBC</i></p> <p>Waiting time in radiotherapy, an overlooked problem: The European perspective</p>	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Poster Viewing 6

		Speaker TBC							
11:40-12:10	Presidential Symposium								
12:10-12:30	Jens Overgaard Legacy Award								
12:30-13:00	Regaud Award Lecture <i>J. Bourhis (CH)</i>								
13:00-14:45	13:30-14:30 GEC-ESTRO Assembly Lunch, Satellite Symposium, Poster Viewing								
14:45-16:00	<p>Symposium</p> <p>New paradigm in HNSCC</p> <p>Chair: E. Lartigau (FR)</p> <p>Modern biomarkers for therapeutic strategy: radiation dose or volume modification <i>M. Krause (DE)</i></p> <p>The changing role of the head and neck surgeon in HPV-positive oropharyngeal squamous cell carcinoma, or do we still need surgery? <i>C. Simon (CH)</i></p> <p>Radiation de-escalation strategies in HPV-positive squamous cell carcinoma <i>J. Giralt (ES)</i></p>	<p>Symposium with proffered papers</p> <p>Costs and value of radiotherapy innovations: how to assess</p> <p>Chair: Y. Lievens (BE)</p> <p>Health Technology Assessment: what's in a word? <i>A. Aggarwal (UK)</i></p> <p>Radiotherapy costs: the good, the bad and the ugly <i>L. Perrier (FR)</i></p> <p>Method of development of ESMO Magnitude of Clinical Benefit applicable for radiotherapy <i>E. De Vries, Groningen (NL)</i></p> <p>+ 1-2 proffered papers</p>	<p>Debate</p> <p>This house believes that proton guided photons will be superior to photon guided protons</p> <p>Chair: J. Deasy (US)</p> <p>For the motion: <i>B. Raaymakers (NL)</i></p> <p>Against the motion <i>A. Lomax (CH)</i></p>	Proffered papers	<p>Symposium</p> <p>Focus on ART: the clinical difficulties</p> <p>Chair: A. Duffton (UK)</p> <p>Multi-parametric functional PET/MR imaging for RT individualisation <i>D. Thorwarth (DE)</i></p> <p>Metabolic and functional MRI for glioblastoma dose-painting trial <i>A. Laprie (FR)</i></p> <p>RAIDER study on plan of the day and dose-escalation for bladder cancer <i>H. McNair (UK)</i></p>	Proffered papers	<p>Symposium</p> <p>Registration and fusion techniques</p> <p>Chair: FA. Siebert (DE)</p> <p>Rigid registration techniques for different imaging modalities <i>N. Nesvacil (AT)</i></p> <p>Deformable registration for dose summation <i>K. Tanderup (DK)</i></p> <p>Imaging and fusion techniques for focal brachytherapy <i>L. Beaulieu (CA)</i></p>		Poster Viewing 7
16:00-16:30	Coffee Break								
16:30-17:30	Proffered Papers	<p>Symposium</p> <p>GTRFCC</p> <p>Session TBA</p>	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Poster Viewing 8

17:40-17:50	Academic Award Lecture Jack Fowler University of Wisconsin Award	
17:50-18:10	Company Award Lectures ESTRO-Varian Award ESTRO-Accuray Award	

MONDAY, 8 MAY 2017

<p>08:00 - 08:40</p>	<p>Teaching Lecture</p> <p>State of the art multimodality treatment of rectal cancer</p> <p>Chair: MA. Gambacorta (IT)</p> <p><i>Speaker: C. Rödel (DE)</i></p>	<p>Teaching Lecture</p> <p>SBRT for spine and non-spine bone metastases: what role in routine practice?</p> <p>Chair: M. Hoyer (DK)</p> <p><i>Speaker: M. Dahele (NL)</i></p>	<p>Teaching Lecture</p> <p>Challenges in proton radiotherapy</p> <p>Chair: M. Krause (DE)</p> <p>How to reduce range uncertainties <i>A. Knopf (NL)</i></p> <p>Adaptation to anatomical changes: needs and pitfalls <i>E. Troost (DE)</i></p>	<p>Teaching Lecture</p> <p>Targeting histones and epigenetic mechanisms in radiation biology and oncology</p> <p>Chair: C. Vens (NL)</p> <p><i>Speaker: AH Ree (NO)</i></p>	<p>Teaching Lecture</p> <p>State of the art and future improvements in in-room cone beam CT image quality</p> <p>Chair: TBC</p> <p><i>Speaker: D. Moseley (CA)</i></p>	<p>Teaching Lecture</p> <p>Radiomics for physicists – understanding feature extraction, quality, selection, prediction modelling, statistics, performance validation and possible applications of radiomics in clinical routine</p> <p>Chair: A. Dekker (NL)</p> <p><i>Speaker: S. Walsh (NL)</i></p>	<p>Teaching lecture</p> <p>Focus on lung cancer: What a radiotherapy department should offer their patients</p> <p>Chair: A. Kostovski (BiH)</p> <p><i>Speaker: M. Guckenberger (CH)</i></p>	<p>Teaching Lecture</p> <p>‘Show me the money’: Tips and tricks on how to write successful grant proposals</p> <p>Chair: T. Gauer (DE)</p> <p><i>Speaker: P. Lambin (NL)</i></p>	
<p>08:45 - 10:00</p>	<p>Symposium</p> <p>Rectal cancer – prediction and individualisation</p> <p>Chair: C. Rödel (DE)</p> <p>Sequence of radiotherapy, chemotherapy, and surgery: current concepts and trials <i>R. Glynn-Jones (UK)</i></p> <p>Organ preservation by optimised radiotherapy: ready for prime time? <i>GL Beets (NL)</i></p>	<p>Symposium</p> <p>Radiotherapy of brain tumours</p> <p>Chair: U. Ricardi (IT)</p> <p>Radiotherapy for low grade glioma in adults: risk group stratification and clinical evidence <i>S. Villa Freixa (ES)</i></p> <p>What is the role of combined chemo-radiotherapy for grade III glioma in adults? <i>A. Chalmers (UK)</i></p>	<p>Symposium with proffered papers</p> <p>MR guided radiotherapy: the new standard of care in 10 years time</p> <p>Chair: J. Lindegaard (DK)</p> <p>Clinical opportunities with MR guided external beam RT <i>M. Van Vulpen (NL)</i></p> <p>MR guided brachytherapy - successes and potential future developments <i>P. Hoskin (UK)</i></p>	<p>Symposium with proffered papers</p> <p>Novel approaches in head and neck tumour control</p> <p>Chair: R. Suwinski (PL)</p> <p>State of the art in head and neck tumour radiobiology <i>Brian O’Sullivan (CA)</i></p> <p>Novel developments in the radiobiology of HPV-positive head and neck tumours <i>S. Nuyts (BE)</i></p>	<p>Symposium</p> <p>Experimental therapies</p> <p>Chair: M. van Herk (NL)</p> <p>Grid therapy: past, present, future <i>A. Siegbahn (SE)</i></p> <p>Strategies for radiosensitisation with gold nanoparticles <i>S. Krishnan (US)</i></p> <p>Potentials of Cerenkov imaging in radiotherapy <i>A. Spinelli (IT)</i></p>	<p>Symposium</p> <p>Adaptive radiotherapy (both anatomical and ‘functional’ changes)</p> <p>Chair: C. Fiorino (IT)</p> <p>Image registration and dose accumulation <i>K. Brock (US)</i></p> <p>Adaptive strategies to account for anatomical changes <i>JJ Sonke (NL)</i></p> <p>Adaptive</p>	<p>Symposium</p> <p>Focus on lung cancer: What a radiotherapy department should offer their patients</p> <p>Chair: M. Kamphuis (NL)</p> <p>PET/CT artefacts for RT planning <i>A. Santos (PT)</i></p> <p>ART in lung cancer: when and for whom? <i>P. Berkovic (BE)</i></p> <p>Improvements in physics, DIBH in lung <i>M. Josipovic (DK)</i></p>	<p>Career Symposium</p> <p>Education and research grants</p> <p>Chair: L. Dubois (NL)</p> <p>ERC grants - how to succeed <i>M. Vooijs (NL)</i></p> <p>ESTRO educational grants and mobility grants <i>MC Vozenin (CH)</i></p> <p>ESTRO Educational Grant - if you don't try, you won't win <i>M. Spalek (PL)</i></p>	<p>Poster Viewing 9</p>

	Imaging and molecular profiles to predict response to chemoradiotherapy: where do we stand? <i>K. Haustermans (BE)</i>	'Paediatric' brain tumours in adults <i>RD Kortmann (DE)</i>	Challenges associated with MR guided radiotherapy <i>D. Jaffray (CA)</i> Can we perform RCTs evaluating MR guided radiotherapy? <i>V. Valentini (IT)</i> + 1-2 proffered papers	+3 proffered papers		strategies to account for functional changes <i>I. Toma-Dasu (SE)</i>		ESTRO mobility grant - Establishing intravital brain imaging in preclinical models <i>J. Birch (UK)</i> Experience with the ESTRO mobility grant; proton irradiation of a 3D dosimeter <i>EM Hoye (DK)</i>	
10:00 - 10:30	Coffee Break								
10:30 - 11:30	Proffered Papers	Multidisciplinary Tumour Board Brain metastases	Joint Symposium ESTRO-ESR Radiomics and imaging databases for precision radiation oncology Chair: V. Valentini (IT) Chair: K. Riklund (SE) Radiomics in radiology, what are the parameters of interest for different imaging modalities? <i>H. Ahlström (SE)</i> Radiomics in Radiotherapy. How is it used to personalise treatment and to predict toxicity and/or Tumor control <i>C. Gani (DE)</i> Uncertainties in imaging how they should be	Symposium with proffered papers Novel approaches in prostate tumour control Chair: N. Cordes (DE) State of the art in prostate tumour radiobiology <i>C. Peitzsch (DE)</i> Novel developments in molecular targeting of prostate cancer <i>R. Bristow (CA)</i> + 1 proffered paper	Proffered Papers	Proffered Papers	Proffered Papers	Keynote Lecture Chair: W. van Elmpt (NL) Title TBA <i>C. Lintott (UK)</i>	Poster Viewing 10

			reported and propagated in prediction models using radiomics <i>L. Muren (DK)</i>						
11:40-11:50	Donal Hollywood Award								
11:50-12:30	Highest scoring abstracts								
12:30-13:00	Breur Award Lecture The 5 R(elevant) principles of radiotherapy in multimodal cancer treatment <i>C. Rödel (DE)</i>								
13:00-14:45	Lunch, Satellite Symposium, Poster Viewing								
14:45-16:15	<p>Symposium</p> <p>Non-rectal GI tumours: key open questions to be answered from (and for) the radiation oncologist!</p> <p>Chair: E. Fokas (DE)</p> <p>Radio(chemo)therapy in oesophageal cancer: can we do better? <i>M. Hulshof (NL)</i></p> <p>Does radiotherapy still have a role in the management of pancreatic cancer? <i>E. Fokas (DE)</i></p> <p>Standard treatment in anal cancer: where do we stand and where should we go?</p>	<p>Symposium</p> <p>Locally advanced breast cancer</p> <p>Chair: P. Lara (ES)</p> <p>Personalised local and locoregional radiotherapy in breast cancer <i>T. Tramm (DK)</i></p> <p>Where should we place radiotherapy: before or after surgery? <i>L. Boersma (NL)</i></p> <p>Radiation therapy after complete response after primary systemic therapy. Is it needed? <i>P. Poortmans (NL)</i></p>	<p>Joint Symposium ESTRO-RANZCR</p> <p>Big data to better radiotherapy</p> <p>Chair: J. Alsner (DK) Chair: S. Turner (AU)</p> <p>The pros, cons, process and challenges for achieving better RT through data-an introduction <i>L. Holloway (AU)</i></p> <p>From radiomics / genomics / radiogenomics data to better RT <i>A. Vega (ES)</i></p> <p>From radiotherapy & dosimetry data to better plans <i>M. Hoogeman (NL)</i></p>	<p>Symposium with proffered papers</p> <p>Novel approaches in lung tumour control</p> <p>Chair: P. Huber (DE)</p> <p>State of the art in lung cancer radiobiology <i>M. Vooijs (NL)</i></p> <p>Secretome as novel target for lung cancer <i>M. Pruschy (CH)</i></p> <p>+ 3 proffered papers</p>	<p>Debate</p> <p>TBA</p>	<p>Proffered papers</p>	<p>Symposium</p> <p>Focus on prostate cancer: what is the best radiotherapy we need to treat our patients with</p> <p>Chair: TBC</p> <p>What are the best ingredients to deliver the optimal radiotherapy for prostate cancer? <i>V. Khoo (UK)</i></p> <p>Spacer / hypofractionation <i>P. Scherer (AT)</i></p> <p>Using an MRI-guided radiation therapy system for prostate cancer patients <i>O. Bohoudi (NL)</i></p>	<p>Scientific symposium</p> <p>Young ESTRO meets ESTRO School</p> <p>Chair: B. De Bari (FR)</p> <p>Introduction and presentation of FALCON (Fellowship in Anatomic delineation and CONtouring) on-line contouring system as a tool for e-learning <i>JG Eriksen (DK)</i></p> <p>Role of radiotherapy in the treatment of stage IIIA/pN2 non-small cell lung cancer Medical student: <i>L. Käsmann (DE)</i></p> <p>Role of radiotherapy in the treatment of</p>	<p>Poster Viewing 11</p>

	<i>R. Muirhead (UK)</i>		How to move Big Data results to clinical practice – a positive outlook <i>S. Vinod (AU)</i>					stage IIIA/pN2 non-small cell lung cancer Senior: <i>B. Jeremic (SR)</i> Cervical cancer: Literature overview and discussion of clinical case Medical student: <i>L. Bolm (DE)</i> Cervical cancer: Literature overview and discussion of clinical case Senior: <i>L. Motisi (IT)</i> Rectal cancer: Literature overview and discussion of clinical case Medical student: <i>I. Barua (NO)</i> Rectal cancer: Literature overview and discussion of clinical case Senior: <i>K. Haustermans (BE)</i>	
16:15-16:45	Coffee Break								
16:45-17:45	Proffered Papers	Proffered Papers	Symposium with proffered papers Patient Reported Outcomes (PROs) in radiotherapy Chair: <i>S. Faithfull (UK)</i> Differences between PRO and clinician reported morbidity and	Symposium with proffered papers Novel approaches in colorectal tumour control Chair: TBC State of the art in colorectal cancer radiobiology <i>J. Bussink (NL)</i>	Proffered Papers	Proffered Papers	Proffered Papers	16:45-17:00 Info from yESTRO Activities and short report from Agora 17:00-17:15 Interactive quiz 17:15-18:00 Young reception	Poster Viewing 12

			<p>associations to clinical outcome <i>K. Kirchheiner (AT)</i></p> <p>Collecting PROs in routine clinical practice to assess radiotherapy toxicity and develop normal tissue complication probability models <i>A. Gilbert (UK)</i></p> <p>PROs instruments used in clinical trials <i>S. Faithful (UK)</i></p> <p>+ 1-2 proffered papers</p>	<p>Immunobiology of gastro-intestinal tumours <i>P. Huber (DE)</i></p> <p>+ 1 proffered paper</p>					
17:50	ESTRO General Assembly								

TUESDAY, 9 MAY 2017

08:30-09:10	<p>Teaching Lecture</p> <p>New radiotherapeutic horizons in soft tissue sarcoma treatment</p> <p>Chair: L. Livi (IT)</p> <p>Speaker: R. Haas (NL)</p>	<p>Teaching Lecture</p> <p>Clinical evidence for hypofractionation in prostate cancer: what is the optimum?</p> <p>Chair: M. van Vulpen (NL)</p> <p>Speaker: P. Blanchard (FR)</p>	<p>Teaching Lecture</p> <p>Extracellular vesicles in radiation oncology</p> <p>Chair: M. Vooijs (NL)</p> <p>Speaker: K. Røe Redalen (NO)</p>	<p>Teaching Lecture</p> <p>Update on molecular radiotherapy</p> <p>Chair: TBC</p> <p>Speaker: G. Flux (UK)</p>	<p>Teaching Lecture</p> <p>Basics, implementations, limitations, ... of Monte Carlo dose calculation algorithms</p> <p>Chair: B. McClean (IE)</p> <p>Speaker: F. Verhaegen (NL)</p>	<p>Teaching Lecture</p> <p>New roles in advanced practice for RTTs</p> <p>Chair: P. Scherer (AT)</p> <p>Speaker: M. Coffey (IE)</p>
09:15-10:30	<p>Symposium</p> <p>Radiotherapy in the elderly</p> <p>Chair: J. Jaal (EE)</p> <p>Radiotherapy in elderly rectal cancer patients <i>R. Nout (NL)</i></p> <p>Breast cancer <i>I. Kunkler (UK)</i></p> <p>Radiotherapy in older patients with GBM <i>G. Minniti (IT)</i></p> <p>Lung cancer <i>J. van Loon (NL)</i></p>	<p>Symposium with proffered papers</p> <p>Selection of patients and radiotherapy technique for APBI in the light of new phase III trial data</p> <p>Chair: J. Guinot (ES)</p> <p>Target coverage and dose to organs at risk using different techniques of APBI (EBI, IORT, BT) <i>L. Marrazzo (IT)</i></p> <p>External beam partial breast irradiation: changing patient selection based on current evidence <i>I. Meattini (IT)</i></p> <p>Partial breast irradiation with brachytherapy: changing patient selection based on current evidence <i>C. Polgár (HU)</i></p> <p>+ 1-2 proffered papers</p>	<p>Symposium with proffered papers</p> <p>Novel approaches in poor tumour control sites</p> <p>Chair: S. Demaria (US)</p> <p>Radiopharmaceuticals in pancreatic cancer: Imaging and therapy <i>B. Cornelissen (UK)</i></p> <p>State of the art precision medicine for benign and malignant brain tumours <i>G. Zadeh (CA)</i></p> <p>Circulating tumor DNA <i>F-C Bidard (FR)</i></p> <p>+ 1 proffered paper</p>	<p>Symposium</p> <p>4D imaging and tracked delivery</p> <p>Chair: D. Verellen (BE)</p> <p>MLC tracking: from bench to bedside <i>M. Fast (UK)</i></p> <p>Motions models and tracking using MR <i>R. Tjissen (NL)</i></p> <p>Tracking: present status and what to expect in the near future <i>T. Ravkilde (DK)</i></p>	<p>Symposium</p> <p>Modelling and treatment customisation</p> <p>Chair: D. Georg (AT)</p> <p>Developments in head and neck toxicity data, models, and treatment optimisation <i>A. van der Schaaf (NL)</i></p> <p>New NTCP data in the thoracic region <i>J. Deasy (US)</i></p> <p>New NTCP data in the pelvic area <i>C. Fiorino (IT)</i></p>	<p>Symposium</p> <p>TBA</p>
10:30-11:00	Coffee Break					
11:00-12:00	<p>Symposium</p> <p>Hypofractionation in prostate cancer</p> <p>Chair: K. Haustermans (BE)</p> <p>Moderate hypofractionation in prostate cancer: what have we learnt from phase 3</p>	<p>Symposium with proffered papers</p> <p>Is there any ground for boost brachytherapy in the time of high precision IGRT/IMRT?</p> <p>Chair: C. Polgar (HU)</p>	<p>Symposium with proffered papers</p> <p>Novel approaches in tumour control</p> <p>Chair: G. Zadeh (CA)</p> <p>Molecular mechanisms of radiation-induced in situ</p>	<p>Symposium</p> <p>Applications and challenges in dosimetry for MR-linacs</p> <p>Chair: C. Clark (UK)</p> <p>Reference dosimetry: getting the basics and calibration</p>	<p>Symposium</p> <p>Novel approaches for combining imaging and non-imaging data for radiotherapy response prediction</p> <p>Chair: D. Thorwarth (DE)</p>	<p>Debate</p> <p>Precision in radiotherapy: mission complete!</p> <p>Chair: M. Mast (NL)</p> <p>For the motion <i>C. Dickie (CA)</i></p>

	<p>trials <i>D. Dearnaley (UK)</i></p> <p>Extreme hypofractionation – the future of prostate care or repeating past mistakes? <i>A. Loblaw (CA)</i></p> <p>Hypofractionation in prostate cancer: a word of caution <i>S. Bentzen (US)</i></p>	<p>The efficacy of IGRT/IMRT simultaneous integrated boost (SIB) in gynaecology and breast <i>M. Ozsahin (CH)</i></p> <p>Dose gradients: the effect of high doses inside the CTV comparing boost brachytherapy with SIB <i>D. Baltas (DE)</i></p> <p>Why use invasive techniques for boost if IGRT is more comfortable for the patient? <i>JL Guinot (ES)</i></p> <p>+ 1-2 proffered papers</p>	<p>tumor vaccination <i>S. Demaria (US)</i></p> <p>Novel developments in paediatric cancer <i>M. McCabe (UK)</i></p> <p>+ 1 proffered paper</p>	<p>right <i>S. Duane (UK)</i></p> <p>Clinical commissioning of MR guided treatment systems <i>O. Green (US)</i></p> <p>Pre-treatment phantom dosimetry: effects in different phantoms and detectors <i>B. van Asselen (NL)</i></p>	<p>Modeling the relation among volume, vascularization and radio-sensitivity in cervical cancer exploiting Doppler ultrasonography data <i>A. Belfatto (IT)</i></p> <p>Machine learning and bioinformatics approaches to combine MP data for outcome prediction <i>O. Gevaert (US)</i></p> <p>Tissue classification models for prostate based on imaging and non-imaging data <i>U. van der Heide (NL)</i></p>	<p>Against the motion <i>A. Duffton (UK)</i></p>
12:00-13:00	Closing Debate					
13:00	Conclusive Remarks					